Israeli foodtech company EFISHient Protein has successful completed the development of a tilapia cell line, with the company saying the achievement signifies a “significant advancement” in the field of cultivated meat technology, paving the way for sustainable cultivated fish production.
Using cutting-edge technological capabilities, EFISHient Protein is now able to produce muscle and fat cells of tilapia, which is a key step towards establishing a genetic cell bank.
“We are thrilled to lead the way in revolutionising the global fish products industry. Completing the tilapia cell line development showcases our dedication to accelerating sustainable protein solutions, ensuring future generations can enjoy nutritious and ethical fish products,” EFISHient Protein CEO Dana Levin said.
According to EFISHient Protein, its partnership with BioMeat Foodtech and the Volcani Institute has been instrumental in combining breakthrough technology with extensive experience in the alternative protein sector.
This collaboration positions EFISHient Protein as a promising player in the cultivated fish industry, it said.
